190 related articles for article (PubMed ID: 1289667)
1. Chemoprevention in prostate cancer: the role of difluoromethylornithine (DFMO).
Kadmon D
J Cell Biochem Suppl; 1992; 16H():122-7. PubMed ID: 1289667
[TBL] [Abstract][Full Text] [Related]
2. Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice.
Gupta S; Ahmad N; Marengo SR; MacLennan GT; Greenberg NM; Mukhtar H
Cancer Res; 2000 Sep; 60(18):5125-33. PubMed ID: 11016639
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine.
Love RR; Carbone PP; Verma AK; Gilmore D; Carey P; Tutsch KD; Pomplun M; Wilding G
J Natl Cancer Inst; 1993 May; 85(9):732-7. PubMed ID: 8478959
[TBL] [Abstract][Full Text] [Related]
4. Copenhagen rat prostatic tumor ornithine decarboxylase activity (ODC) and the effect of the ODC inhibitor alpha-difluoromethylornithine.
Heston WD; Kadmon D; Lazan DW; Fair WR
Prostate; 1982; 3(4):383-9. PubMed ID: 6812032
[TBL] [Abstract][Full Text] [Related]
5. Polyamines as biomarkers of cervical intraepithelial neoplasia.
Nishioka K; Melgarejo AB; Lyon RR; Mitchell MF
J Cell Biochem Suppl; 1995; 23():87-95. PubMed ID: 8747382
[TBL] [Abstract][Full Text] [Related]
6. Chemoprevention of prostate cancer with the polyamine synthesis inhibitor difluoromethylornithine.
Meyskens FL; Simoneau AR; Gerner EW
Recent Results Cancer Res; 2014; 202():115-20. PubMed ID: 24531785
[TBL] [Abstract][Full Text] [Related]
7. Differential sensitivity of various human tumors to inhibition of polyamine biosynthesis in vivo.
Saydjari R; Alexander RW; Upp JR; Barranco SC; Townsend CM; Thompson JC
Int J Cancer; 1991 Jan; 47(1):44-8. PubMed ID: 1985877
[TBL] [Abstract][Full Text] [Related]
8. Marked and prolonged inhibition of mammalian ornithine decarboxylase in vivo by esters of (E)-2-(fluoromethyl)dehydroornithine.
Mamont PS; Danzin C; Kolb M; Gerhart F; Bey P; Sjoerdsma A
Biochem Pharmacol; 1986 Jan; 35(2):159-65. PubMed ID: 3080004
[TBL] [Abstract][Full Text] [Related]
9. A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma.
Saulnier Sholler GL; Gerner EW; Bergendahl G; MacArthur RB; VanderWerff A; Ashikaga T; Bond JP; Ferguson W; Roberts W; Wada RK; Eslin D; Kraveka JM; Kaplan J; Mitchell D; Parikh NS; Neville K; Sender L; Higgins T; Kawakita M; Hiramatsu K; Moriya SS; Bachmann AS
PLoS One; 2015; 10(5):e0127246. PubMed ID: 26018967
[TBL] [Abstract][Full Text] [Related]
10. Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
Meyskens FL; Gerner EW
Clin Cancer Res; 1999 May; 5(5):945-51. PubMed ID: 10353725
[TBL] [Abstract][Full Text] [Related]
11. Individual and combined effects of alpha-difluoromethylornithine and ovariectomy on the growth and polyamine milieu of experimental breast cancer in rats.
Manni A; Badger B; Glikman P; Bartholomew M; Santner S; Demers L
Cancer Res; 1989 Jul; 49(13):3529-34. PubMed ID: 2499419
[TBL] [Abstract][Full Text] [Related]
12. Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine.
Carbone PP; Douglas JA; Larson PO; Verma AK; Blair IA; Pomplun M; Tutsch KD
Cancer Epidemiol Biomarkers Prev; 1998 Oct; 7(10):907-12. PubMed ID: 9796636
[TBL] [Abstract][Full Text] [Related]
13. The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial.
Simoneau AR; Gerner EW; Nagle R; Ziogas A; Fujikawa-Brooks S; Yerushalmi H; Ahlering TE; Lieberman R; McLaren CE; Anton-Culver H; Meyskens FL
Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):292-9. PubMed ID: 18268112
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine.
Qu N; Ignatenko NA; Yamauchi P; Stringer DE; Levenson C; Shannon P; Perrin S; Gerner EW
Biochem J; 2003 Oct; 375(Pt 2):465-70. PubMed ID: 12859253
[TBL] [Abstract][Full Text] [Related]
15. Revival of 2-(difluoromethyl)ornithine (DFMO), an inhibitor of polyamine biosynthesis, as a cancer chemopreventive agent.
Raul F
Biochem Soc Trans; 2007 Apr; 35(Pt 2):353-5. PubMed ID: 17371277
[TBL] [Abstract][Full Text] [Related]
16. AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport.
Samal K; Zhao P; Kendzicky A; Yco LP; McClung H; Gerner E; Burns M; Bachmann AS; Sholler G
Int J Cancer; 2013 Sep; 133(6):1323-33. PubMed ID: 23457004
[TBL] [Abstract][Full Text] [Related]
17. Differential effect of alpha-difluoromethylornithine on the in vivo uptake of 14C-labeled polyamines and methylglyoxal bis(guanylhydrazone) by a rat prostate-derived tumor.
Heston WD; Kadmon D; Covey DF; Fair WR
Cancer Res; 1984 Mar; 44(3):1034-40. PubMed ID: 6420052
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of methylglyoxal-bis-guanylhydrazone by alpha-difluoromethylornithine in rat prostate cancer.
Herr HW; Kleinert EL; Relyea NM; Whitmore WF
Cancer; 1984 Mar; 53(6):1294-8. PubMed ID: 6420041
[TBL] [Abstract][Full Text] [Related]
19. Alpha-difluoromethylornithine (DFMO) as a potent arginase activity inhibitor in human colon carcinoma cells.
Selamnia M; Mayeur C; Robert V; Blachier F
Biochem Pharmacol; 1998 Apr; 55(8):1241-5. PubMed ID: 9719479
[TBL] [Abstract][Full Text] [Related]
20. Attenuation of isoproterenol-mediated myocardial injury in rat by an inhibitor of polyamine synthesis.
Tipnis UR; He GY; Li S; Campbell G; Boor PJ
Cardiovasc Pathol; 2000; 9(5):273-80. PubMed ID: 11064274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
